Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Exclusion Criteria

• •Hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator.
• •Findings of chronic hepatitis B virus (HBV) infection or past HBV.
• •Current or chronic history of liver disease.
• •History of malignancy within 5 years of screening except for adequately-treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
• •Past or current use of cabotegravir, lenacapavir, or any other long-acting HIV prevention product.
• •Currently participating in or has participated in an interventional clinical study with an investigational compound or device, within 30 days prior to Day 1.
• •Expecting to conceive or donate eggs at any time during the study.